Press coverage about ObsEva (NASDAQ:OBSV) has been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ObsEva earned a news impact score of 0.04 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.9952328360897 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of ObsEva (NASDAQ OBSV) opened at $9.70 on Friday. ObsEva has a 1-year low of $5.00 and a 1-year high of $14.69.
ObsEva (NASDAQ:OBSV) last announced its quarterly earnings results on Tuesday, November 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.01). The company’s quarterly revenue was up NaN% on a year-over-year basis. sell-side analysts expect that ObsEva will post -2.31 earnings per share for the current year.
A number of research firms have weighed in on OBSV. HC Wainwright set a $25.00 price objective on shares of ObsEva and gave the company a “buy” rating in a research note on Thursday, January 4th. Zacks Investment Research downgraded shares of ObsEva from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. BMO Capital Markets began coverage on shares of ObsEva in a report on Monday, December 4th. They set an “outperform” rating and a $20.00 price target on the stock. Royal Bank of Canada reaffirmed a “buy” rating and set a $22.00 price target on shares of ObsEva in a report on Thursday, November 2nd. Finally, Credit Suisse Group began coverage on shares of ObsEva in a report on Monday, October 9th. They set an “outperform” rating and a $16.00 price target on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $19.00.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect ObsEva (OBSV) Share Price” was originally published by Stock Observer and is the property of of Stock Observer. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.thestockobserver.com/2018/01/13/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-obseva-obsv-share-price.html.
ObsEva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.